Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Alleviating effects of AS1892802, a Rho kinase inhibitor, on osteoarthritic disorders in rodents.

Takeshita N, Yoshimi E, Hatori C, Kumakura F, Seki N, Shimizu Y.

J Pharmacol Sci. 2011;115(4):481-9. Epub 2011 Feb 16.

2.

Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis.

Yoshimi E, Kumakura F, Hatori C, Hamachi E, Iwashita A, Ishii N, Terasawa T, Shimizu Y, Takeshita N.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):955-63. doi: 10.1124/jpet.110.167924. Epub 2010 Jun 9.

PMID:
20534789
3.

Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.

Sawada Y, Kayakiri H, Abe Y, Mizutani T, Inamura N, Asano M, Hatori C, Aramori I, Oku T, Tanaka H.

J Med Chem. 2004 May 20;47(11):2853-63.

PMID:
15139763
4.

A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.

Sawada Y, Kayakiri H, Abe Y, Mizutani T, Inamura N, Asano M, Aramori I, Hatori C, Oku T, Tanaka H.

J Med Chem. 2004 May 6;47(10):2667-77.

PMID:
15115408
5.

A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.

Sawada Y, Kayakiri H, Abe Y, Imai K, Mizutani T, Inamura N, Asano M, Aramori I, Hatori C, Katayama A, Oku T, Tanaka H.

J Med Chem. 2004 Mar 25;47(7):1617-30.

PMID:
15027853
6.

Novel potent antagonists of human neuropeptide Y-Y5 receptor. Part 4: tetrahydrodiazabenzazulene derivatives.

Satoh Y, Hatori C, Ito H.

Bioorg Med Chem Lett. 2002 Apr 8;12(7):1009-11.

PMID:
11909705
7.

Nonpeptide mimic of bradykinin with long-acting properties.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H, Kayakiri H, Satoh S, Inoue T, Abe Y, Sawada Y, Mizutani T, Inamura N, Iwami M, Nakahara K, Kojo H, Oku T, Notsu Y.

Immunopharmacology. 1999 Dec;45(1-3):185-90.

PMID:
10615010
8.

Discovery of orally active nonpeptide bradykinin B2 receptor antagonists.

Asano M, Inamura N, Hatori C, Sawai H, Fujiwara T, Abe Y, Kayakiri H, Satoh S, Oku T, Nakahara K.

Immunopharmacology. 1999 Sep;43(2-3):163-8. Review.

PMID:
10596849
9.

Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on guinea-pig tracheal smooth muscle bradykinin receptors.

Asano M, Sawai H, Hatori C, Inamura N, Fujiwara T, Nakahara K.

Can J Physiol Pharmacol. 1998 Oct-Nov;76(10-11):1051-5.

PMID:
10100888
10.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.

Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N, Asano M, Aramori I, Hatori C, Sawai H, Oku T, Tanaka H.

J Med Chem. 1998 Nov 5;41(23):4587-98.

PMID:
9804698
11.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.

Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N, Asano M, Aramori I, Hatori C, Sawai H, Oku T, Tanaka H.

J Med Chem. 1998 Oct 8;41(21):4062-79.

PMID:
9767643
12.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.

Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N, Asano M, Hatori C, Sawai H, Oku T, Tanaka H.

J Med Chem. 1998 Oct 8;41(21):4053-61.

PMID:
9767642
13.

Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997.

Asano M, Hatori C, Sawai H, Johki S, Inamura N, Kayakiri H, Satoh S, Abe Y, Inoue T, Sawada Y, Mizutani T, Oku T, Nakahara K.

Br J Pharmacol. 1998 Jun;124(3):441-6.

14.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.

Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Imai K, Inamura N, Asano M, Hatori C, Katayama A, Oku T, Tanaka H.

J Med Chem. 1998 Feb 12;41(4):564-78.

PMID:
9484506
15.

Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammation.

Asano M, Hatori C, Inamura N, Sawai H, Hirosumi J, Fujiwara T, Nakahara K.

Br J Pharmacol. 1997 Dec;122(7):1436-40.

16.

Pharmacological characterization of a novel, orally active, nonpeptide bradykinin B2 receptor antagonist, FR167344.

Inamura N, Asano M, Hatori C, Sawai H, Hirosumi J, Fujiwara T, Kayakiri H, Satoh S, Abe Y, Inoue T, Sawada Y, Oku T, Nakahara K.

Eur J Pharmacol. 1997 Aug 20;333(1):79-86.

PMID:
9311664
17.

Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H, Kayakiri H, Satoh S, Inoue T, Abe Y, Sawada Y, Mizutani T, Inamura N, Nakahara K, Kojo H, Oku T, Notsu Y.

Mol Pharmacol. 1997 Jul;52(1):16-20.

PMID:
9224807
18.

Characterization of FR173657, a novel nonpeptide B2 antagonist: in vitro and in vivo studies.

Inamura N, Asano M, Kayakiri H, Hatori C, Oku T, Nakahara K.

Can J Physiol Pharmacol. 1997 Jun;75(6):622-8.

PMID:
9276139
19.

The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657.

Asano M, Inamura N, Hatori C, Sawai H, Fujiwara T, Katayama A, Kayakiri H, Satoh S, Abe Y, Inoue T, Sawada Y, Nakahara K, Oku T, Okuhara M.

Br J Pharmacol. 1997 Feb;120(4):617-24.

Supplemental Content

Loading ...
Support Center